Instructions for Credit - There is no fee for this activity. In order to receive CME or CE credit, attendees must view the program, complete the post-assessment with a score of 70% or higher, and complete the activity evaluation in order to obtain CE credit. After completing this process, you will receive your certificate by email.

Target Audience:
This activity is intended for physicians, physician assistants/associates, and nurses engaged in the care of patients with hematologic malignancies.

Course content level for social workers: all levels

Learning Objectives:
At the conclusion of this activity, participants will be able to:

  • Describe the underlying science and mechanisms of bispecific therapies
  • Identify current and emerging indications for bispecific therapies for hematologic malignancies
  • Assess the clinical evidence on the efficacy, safety, and potential side effects of bispecific therapies
  • Develop strategies for incorporating bispecific therapies into clinical practice
  • Describe the treatment process and mechanisms to improve patient understanding, care, and involvement
  • Discuss challenges and potential future advancements in bispecific antibody development

Faculty:
Luciano Costa, MD, PhD
Professor of Medicine
Mary and Bill Battle Professor of Multiple Myeloma
The University of Alabama at Birmingham
Birmingham, AL

Elise Curry, BA, BSN, RN, OCN
Clinical Trial Nurse Navigator
Clinical Trial Support Center
The Leukemia & Lymphoma Society
Washington, DC

Peter Martin, MD
Professor of Medicine
Chief of the Lymphoma Program
Weill Cornell Medicine
New York, NY

Joint Accreditation Statement:

 In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The Leukemia & Lymphoma Society. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credits:

Physician Continuing Medical Education

 The Postgraduate Institute for Medicine designates this CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Credit Designation

 Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Continuing Physician Assistant Education

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education

 This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

There are no fees for participating in or receiving credit for this activity.

Accredited Providers:
The associates of Postgraduate Institute for Medicine and The Leukemia & Lymphoma Society, the accredited providers for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE activity during the past 24 months.

Disclosure of Financial Relationship
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

  • Luciano Costa reports Grant/Research Support from BMS, Johnson & Johnson, Pfizer, AbbVie, Caribou, Genentech, and Gracel, and Consultant/Advisory Board for BMS, Johnson & Johnson, Pfizer, AbbVie, Caribou, Genentech, Regeneron, Adaptive Biotechnologies, and AstraZeneca.
  • Peter Martin reports Consultant/Advisory Board for Abbvie, AstraZeneca, Beigene, BMS, Genentech, Janssen, Pepromene, and Merck.
  • Elise Curry reports Patient advisory board member for Viracta Pharmaceuticals with compensation provided to LLS.

Peer Reviewers
The Postgraduate Institute for Medicine planners and others have nothing to disclose.

Disclaimer:
The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.

Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Supporters:
There is no commercial support associated with this CME/CE activity.

System Requirements:
An active internet connection with Web browser is required to view this activity.



Estimated time to complete activity: 1.0 hour
Date of initial release: May 7, 2025
Valid for CME/CE credit through: November 5, 2026

For questions, concerns, or for assistance for people with disabilities or grievances, please contact ProfEducation@LLS.org